Amgen Inc header image

Amgen Inc

AMGN

Equity

ISIN null / Valor 907582

NASDAQ (2026-07-06)
USD 366.44-2.06%

Amgen Inc
UMushroom community rating:

star star star star star
4.00 2 votes No rating yet
NegativeNeutralPositive

About company

Amgen Inc. is a global biopharmaceutical company based in Thousand Oaks, California, that discovers, develops, manufactures and markets protein- and antibody-based therapies for serious illnesses; its commercial portfolio and pipeline focus on areas such as oncology, hematology and supportive care, nephrology, bone disease, cardiovascular disease and inflammation, and it also participates in the biosimilars market. The company’s business model combines research and late-stage development of biologics with in-house manufacturing and global commercial operations, with well-known marketed products that have included Epogen and Neulasta (supporting hematologic indications), Enbrel (inflammatory disease), Repatha (cardiovascular risk) and Prolia/Xgeva (bone health). Amgen is publicly traded and derives the bulk of its revenue from therapeutic product sales while continuing to invest in R&D to replenish and expand its pipeline.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

22.9%1Y
64.3%3Y
50.4%5Y

Performance

27.8%1Y
26.1%3Y
24.0%5Y

Volatility

Market cap

197771 M

Market cap (USD)

Daily traded volume (Shares)

2,838,007

Daily traded volume (Shares)

1 day high/low

261.55 / 258.74

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.00

2 votes
Performance:
starstarstarstarstar
4.00
Innovation:
starstarstarstarstar
4.00
Society:
starstarstarstarstar
3.00
Nature:
starstarstarstarstar
3.00
Zoe Holloway
United Kingdom, 07 Feb 2026
star star star star star
Steady upwards trend
Kendra Ho
United Kingdom, 06 Feb 2026
star star star star star
Overall good performance

EQUITIES OF THE SAME SECTOR

Gyre Therapeutics Inc
Gyre Therapeutics Inc Gyre Therapeutics Inc Valor: 130270397
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.09%USD 7.26
IVF HARTMANN Holding AG
IVF HARTMANN Holding AG IVF HARTMANN Holding AG Valor: 18762425
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%CHF 129.00
Bright Horizons Family Solutions
Bright Horizons Family Solutions Bright Horizons Family Solutions Valor: 19920287
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.76%USD 75.71
CG Oncology Inc
CG Oncology Inc CG Oncology Inc Valor: 131996952
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.56%USD 69.26
Douglas AG
Douglas AG Douglas AG Valor: 133507391
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.04%EUR 8.18
SOLVENTUM CORP
SOLVENTUM CORP SOLVENTUM CORP Valor: 133635906
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.42%USD 77.94
Emeis
Emeis Emeis Valor: 132546338
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.55%EUR 14.57
Haemonetics Corp
Haemonetics Corp Haemonetics Corp Valor: 937449
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.07%USD 75.02
AMN Healthcare Services Inc
AMN Healthcare Services Inc AMN Healthcare Services Inc Valor: 1269241
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.94%USD 35.77
Edgewise Therapeutics Inc
Edgewise Therapeutics Inc Edgewise Therapeutics Inc Valor: 110444153
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.37%USD 40.10